Top Abstract Purchase Related
Home
>
Node
>
Subnode

Experience of the use of silodosin in acute urinary retention caused by benign prostatic hyperplasia

Neĭmark, A.I.; Nozdrachev, N.A.

Urologiia 4: 47-48; 50-51

2013

ISSN/ISBN: 1728-2985
PMID: 24159765
Document Number: 669278
For the treatment of acute urinary retention (AUR) as one of the most serious complications of adenoma of the prostate (BPH), alpha-adrenoblockers are widely used. The article presents an experience of the use of the new uroselective alpha-adrenoblocker silodosin approved for the treatment of patients with urination disorders caused by BPH. Its pharmacological profile has a number of advantages, including the highest uroselectiveness at the present day, immediate action, the potential for the use of standard dose of 8 mg 1 time a day, which does not require a correction depending on the age, and the possibility of the simultaneous application with antihypertensive drugs.

Document emailed within 1 workday
Secure & encrypted payments

Kupriyanov, Y.A.; Rasner, P.I.; Rokhlikov, I.M.; Akrikidi, A.A.; Soloviev, V.V.; Markov, A.A.; Nozdrin, E.V.; Logvinov, L.A.; Vasilevskiy, R.P.; Skrupskiy, K.S.; Pushkar, D.Y.; Putilovskiy, M.A.; Epstein, O.I. 2019: The experience of using drug Afalaza for treatment of lower urinary symptoms in treatment-nave patients with benign prostatic hyperplasia Urologiia 3: 36-42
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111
Li, Y.-Z.; Liang, W.-N.; Zhang, G.-W.; Weng, Z.-Q.; Zhong, Y.; Xu, S.; Shang, X.-J. 2019: Efficacy and safety of lycopene in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms Zhonghua Nan Ke Xue 25(11): 1001-1004
Cornu, J-Nicolas.; Rouprêt, M. 2007: Impact of nocturia on the daily life of patients with lower urinary tract symptoms due to benign prostatic hyperplasia Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(5 Suppl 1: 1033-1036
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Pytel', I.A.; Lopatkin, N.A.; Gorilovskiĭ, L.M.; Vinarov, A.Z.; Sivkov, A.V.; Medvedev, A.A. 2004: The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia Urologiia 2: 3-7
Ben Rhouma, S.; H'sairi, M.; Adbi, H.; Binous, M.Y.; Nouira, Y.; Ben Raies, N.; Mosbah, A.T.; Horchani, A. 2015: Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia La Tunisie Medicale 93(3): 164-169
Deng, Z.-X.; Ji, L.-X.; Zhang, Y.-R.; Li, C.-d.; Cai, J.; Jiang, H.-H. 2018: Ningmitai Capsules relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia : a short-term clinical observation Zhonghua Nan Ke Xue 24(1): 72-77
Kongkanand, A.; Chodchoy, V.; Lojanapiwat, B.; Pumpaisanchai, S.; Ratana-Olarn, K.; Sae-Tang, P.; Taweemonkongsap, T. 2009: Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Journal of the Medical Association of Thailand 92(7): 969-978
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Abdul-Muhsin, H.M.; Jakob, N.J.; McLemore, R.M.; McAdams, S.B.; Humphreys, M.R. 2016: Infectious complications associated with the use of temporary prostatic urethral stents in patients with benign prostatic hyperplasia Canadian Journal of Urology 23(5): 8465-8470
Blanc, M.; Sacrini, A.; Avogadro, A.; Gattamorta, M.; Lazzerini, F.; Gattoni, F.; Cretti, F. 1998: Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia La Radiologia Medica 95(3): 182-187
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Pretlow, T.G.; Whitehurst, G.B.; Pretlow, T.P.; Hunt, R.S.; Jacobs, J.M.; McKenzie, D.R.; McDaniel, H.G.; Hall, L.M.; Bradley, E.L. 1982: Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia Cancer Research 42(11): 4842-4848
Fukui, S.; Iemura, Y.; Matsumura, Y.; Kagebayashi, Y.; Hotta, Y.; Yoshida, S.; Samma, S. 2018: Acute Urinary Retention Caused by Acute Disseminated Encephalomyelitis : A Case Report Hinyokika Kiyo. Acta Urologica Japonica 64(1): 17-20
Chepurov, A.K.; Krivoborodov, G.G.; Raksha, A.P.; Malenko, V.P.; Shvarts, P.G. 2001: Acute urinary retention caused by urethral polyp Urologiia 2: 45-47
Maygarden, S.J.; Strom, S.; Ware, J.L. 1992: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia Archives of Pathology and Laboratory Medicine 116(3): 269-273
Ibishev, K.S.; Krainy, P.A.; Mitusov, V.V.; Sizyakin, D.V.; Magomedov, G.A. 2019: A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue Urologiia 1: 40-46